News of Epidiolex And On Posting Impressive Results, GW Pharmaceuticals Plc (OTCMKTS:GWPRF) Records Weekly Gains of 10% in Stock Price

GW Pharmaceuticals Plc (OTCMKTS:GWPRF) clocked weekly gains of 10% on reporting impressive results and on the news of Epidiolex, a famed drug. It beat the analysts’ expectations and posted better than expected results in the latest quarter.

Impressive sales of Epidiolex

GW Pharmaceuticals posted impressive sales of Epidiolex, a cannabis derived drug. The FDA approved drug is used for the treatment of childhood epilepsy. The company began the sales of Epidiolex in November 2018. The drug contributed sales of $33.5 million of the total sales of $39.5 million of GW Pharmaceuticals.

Phase 3 trial of Epidiolex

GW Pharmaceuticals is pleased to announce positive results of Epidiolex during phase 3 clinical trial. The company conducted phase 3 trial to test the effectiveness of Epidiolex in treating patients suffering from TSC (Tuberous Sclerosis Complex), a severe epilepsy in the childhood.

The drug has shown a considerable reduction in the seizure frequency from the baseline than placebo during the trial. It is the 5th consecutive trial for the drug and reiterates the success. GW Pharmaceuticals plans for the launch of an oral solution – Epidiolex in the five major markets of Europe in the later part of 2019.

The CEO of GW Pharmaceuticals, Justin Gover will be present in Las Vegas on May 15, 2019, Wednesday at the BOA (Bank of America) Merrill Lynch Healthcare Conference.

GW Pharmaceuticals and Greenwich Biosciences, the US subsidiary, will showcase the phase 3 clinical trials of oral solution – Epiodiolex at AAN (American Academy of Neurology) annual conference in Philadelphia on May 4, 2019. The company will present the effectiveness of the drug in treating Dravet Syndrome and Lennox Gastaut syndrome with supporting data.

Justin Gover said the community in the US has well accepted the drug to treat seizures. It is a highly purified cannabidiol sold on prescription.


Epidiolex is not recommended for people, who are allergic to any ingredients in this oral solution or CBD. The physician prescribes blood test of the patients to check the health of liver before and after the usage of Epidiolex. The patients need to seek urgent attention of a physician in case of symptoms: fever, nausea, loss of appetite, and itching.


Marapharm Ventures Inc (OTCMKTS:MRPHF) Signs A LOI To Acquire Full Spectrum Medicinal Inc

Marapharm Ventures Inc (OTCMKTS:MRPHF) has signed a letter of intent to take over Full Spectrum Medicinal Inc. The company has set September 30, 2018, as the deadline to conduct due diligence on Full Spectrum and complete the acquisition.

Following the takeover, Marapharm Ventures will merge Full Spectrum application with Health Canada Application. It helps to become a licensed cannabis manufacturer of premium flower for commercial use. The company will be able to deliver organic and quality cannabis products in a cost-effective way and boost profits.

The business model of the company is to build standardized engineered bio-secure facilities. The state of the art facilities are scalable and saves energy and promote cost-effective cultivation. The company will be able to grow quality cannabis indoors at reduced costs. Marapharm Ventures will deliver the first assembly building at an approved site situated near the Salmon Arm, British Columbia.

The company is planning for penetration of the legal cannabis with edibles, oils, and flowers and build a long-term value in the rapidly growing market.

Canada Legalizes Marijuana

Justin Trudeau, Prime Minister, Canada has announced the legalization of marijuana on June 20, 2018. The legalization of marijuana comes into effect from October 17, 2018. It has put an end to the prohibition of cannabis in Canada.

Marapharm Ventures Inc Issues an Update on Market Activities to The Shareholders As Frankfurt’s Clearstream Closes Doors to The North American cannabis stocks

Marapharm Ventures Inc has issued an update on the recent market activities to the shareholders on the backdrop of Frankfurt’s Clearstream shutting the doors to North American Cannabis stocks.

Frankfurt, Germany based major central securities depository – Clearstream has set June 29, 2018, as the deadline as for final settlements free of fee. However, Clearstream will offer the services till September 28, 2018, and after that it will not settle the securities related to cannabis and narcotic products due to legal reasons.

The list of impacted securities include GW Pharmaceuticals PLC (NASDAQ:GWPH), Canopy Growth Corp (NYSE:CGC), Aurora Cannabis Inc (OTCMKTS:ACBFF), and Marapharm Ventures Inc.

Marapharm Ventures Inc has a number of Germany based shareholders. The company is making alternative arrangements in view of the sudden decision of Clearstream.


GW Pharmaceuticals Plc (NASDAQ:GWPH) Appoints Two Top Officials

GW Pharmaceuticals Plc (NASDAQ:GWPH) has announced its bringing on board Scott Giacobello to serve in the capacity of the Chief Financial Officer. The company through its cannabinoid product platform has over the years engaged in the discovery, development as well as commercialization of novel products and still hopes to do much more in years to come towards promoting good health around the globe.

The company’s headquarters in the U.S are located in Carlsbad, California and this is where the new top official will be based. He will be reporting to the leading company’s Chief Executive Officer Justin Gover and during this appointment all eyes are focused on him to see what value and contribution he brings to the company.

Some time back, there was a growing need for the company to set up a new executive role. In line with Scott Giacobello’s appointment was the appointment Adam George, to serve in the capacity of Managing Director UK. The newly established role had a wide array of responsibilities linked to UK operations. This official was and still continues to be answerable to GW’s Chief Executive Officer Justin Gover.

Justin Gover lately made some remarks stating that the company is headed towards a promising future even by the look of the appointments it has been making lately. He termed them important leadership appointments which happen to be an on-point reflection of what the company has grown to become in the direction of evolving to become a significant transatlantic commercial-stage biopharmaceutical provider.

At the moment, the company awaits the Epidiolex approval and launch as well and according to the top executive; it is a good thing that the company is listed on NASDAQ. As an organization, they are prepared to make the transition from being a Foreign Private Issuer reporting under IFRS to moving a notch-higher to be the domestic registrant reporting and this will be under the umbrella of the US GAAP.

Giacobello boasts of a wealth of experience after working in a number of top positions. However, the latest have been his serving at Black and Decker Corporation not of course forgetting Ernst and Young. He happens to be a Certified Public Accountant and a proud holder of a bachelor’s degree in business administration which he obtained from University of Notre Dame.

While we are still talking about MMJ companies, a micro cap company that needs mention is American Premium Water (HIPH). As per today’s press release, the company is looking forward to launch its CBD-water. “We are excited to be increasing our reach in the most sought out industry in America. CBD is a non-psychoactive byproduct of the hemp plant, widely believed to have numerous health benefits. As a Naturalist, I feel that our customers deserve to live a healthy lifestyle,” said Founder Alfred T. Culbreth. Click HERE to read more on HIPH.


GW Pharmaceuticals plc (NASDAQ:GWPH) Presents New Epidiolex Data

GW Pharmaceuticals plc (NASDAQ:GWPH) has presented new encouraging data from two Phase 3 clinical trials evaluating Epidiolex (cannabidiol [CBD]) for the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS), respectively, at the 70th Annual Meeting of the American Epilepsy Society (AES).

Presentation Highlights

Both the Phase 3 clinical trials achieved their respective primary endpoints as Epidiolex had demonstrated a significant improvement in minimizing seizure frequency compared to placebo during the 14-week treatment period. Moreover, the effect of the treatment had significantly increased during the 12-week maintenance period among patients administered with Epidiolex compared to patients administered with placebo.

More importantly, in both clinical trials, the tolerability of Epidiolex had been established. Generally, Epidiolex has been proven to minimize seizure frequency significantly without compromising a compelling safety and tolerability profile.

Epidiolex Commercialization

In line with these positive results, the company hopes to hasten its New Drug Application (NDA) submission to the US Food and Drug Administration (FDA).

“We are making very good progress toward a NDA submission to the FDA as well as preparations for commercial launch and look forward to the opportunity to make this important new medicine available to patients as quickly as possible,” reiterated Justin Gover, GW Pharmaceuticals CEO.

GW Pharmaceuticals has been developing CBD for the treatment of some epilepsy disorders since 2007.

The epileptic community is not the only one delighted with this significant advancement. Healthcare providers are likewise pleased to have a new potential prescription that can improve the lives of epileptic patients.

Dravet syndrome is associated with genetic mutations, specifically in sodium channels. On the other hand, LGS is commonly associated with severe brain damages, metabolic conditions, central nervous system infections, among others. Both of these illnesses are strongly treatment-resistant.

Consequently, Dravet syndrome and LGS are characterized with some of the most difficult epilepsy occurrences to treat. With the prospective commercialization of Epidiolex, Dravet syndrome and LGS patients can enjoy the availability of a new and effective treatment option.

On Monday, GW Pharmaceuticals has closed at $117.45, up by 4.57%.


Pin It on Pinterest